CliffBio
small molecule

VISTIDE

CIDOFOVIR

Loss of exclusivity—loss of exclusivity
CompanyGilead Sciences →See this company's full patent-cliff portfolio

Drug detail

Brand nameVISTIDE
Active ingredientCIDOFOVIR
StrengthEQ 375MG BASE/5ML (EQ 75MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 1996
Marketing statusDISCN

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.